Completed

Efficacy of Hydrolyzed Collagen and Undenatured Collagen Type II in Alleviating Pain in Patients With Knee Osteoarthritis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Collagen

+ Placebo

Dietary SupplementOther
Who is being recruted

Arthritis+2

+ Joint Diseases

+ Musculoskeletal Diseases

From 50 to 80 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: November 2023
See protocol details

Summary

Principal SponsorPrince of Songkla University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2023

Actual date on which the first participant was enrolled.

This study is investigating the effectiveness of two types of collagen supplements, hydrolyzed collagen and undenatured type II collagen, in reducing knee pain for patients with osteoarthritis. Osteoarthritis is a common condition that causes joint pain and stiffness, often affecting the knees, which can significantly impact daily activities and quality of life. By exploring new treatment options like collagen supplements, the study aims to find alternative ways to manage pain and improve the lives of those suffering from this condition. Participants in this study are randomly assigned to one of two groups. One group receives a daily dose of 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen, while the other group receives a placebo, which is a substance with no active ingredients. The main focus of the study is to measure changes in pain levels among the participants to evaluate the effectiveness of the collagen supplements. This controlled setup helps determine if these supplements can provide a real benefit in managing osteoarthritis pain.

Official TitleEfficacy of Hydrolyzed Collagen and Undenatured Collagen Type II in Alleviating Pain in Patients With Knee Osteoarthritis
NCT06229951
Principal SponsorPrince of Songkla University
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

68 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 50 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

ArthritisJoint DiseasesMusculoskeletal DiseasesOsteoarthritisRheumatic Diseases

Criteria

4 inclusion criteria required to participate
Age: 50-80 years old
Medial compartment knee osteoarthritis
Kellgren and Lawrence classification stage 2 -3
Able to walk without walking aid
5 exclusion criteria prevent from participating
History of knee surgery on the study side
History of intra-articular steroid injection within 6 months prior to study entry
Systemic arthritis conditions
Degenerative neurological and muscular conditions in the lower extremities
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Patients who have taken 480 mg of hydrolyzed collagen and 20 mg of undenatured type II collagen (in one tablet) 2 tabs a day

Group II

Placebo
Control patients will take placebo 2 tabs a day

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Prince of Songkla University

Hat Yai, ThailandOpen Prince of Songkla University in Google Maps
CompletedOne Study Center